1 results match your criteria: "University Hospital Basel ludwig.kappos@usb.ch.[Affiliation]"
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Mult Scler
April 2016
Neurology, Departments of Medicine, Clinical Research and Biomedicine, University Hospital Basel
Objectives: To explore long-term effects of treatment and prognostic relevance of variables assessed at baseline and during the European secondary progressive multiple sclerosis (SPMS) trial of interferon beta 1b (IFNB-1b).
Methods: We assessed 362 patients (60% female; median age 41 years; Expanded Disability Status Scale (EDSS): 5.5; 51% randomized to IFNB-1b) for their EDSS and treatment history after 10 years.